1. Clinical Updates in RA: New Developments and Insights From Washington

2. Program Overview

3. Program Overview (cont)

4. Dose Reductions in Patients With Rheumatoid Arthritis

5. Sarilumab Dose Reduction in RA Patients

6. Findings

7. Conclusions

8. Reduction of Corticosteroids or Methotrexate With Adalimumab

9. Findings

10. Conclusions

11. Loss of Therapeutic Response in Patients With Rheumatoid Arthritis

12. Loss of Response With a TNF Inhibitor and/or Methotrexate in RA

13. Findings

14. Conclusions

15. Association Between Flare and Radiographic Progression in RA

16. Methods

17. Findings

18. Conclusions

19. Medication Switching in Rheumatoid Arthritis

20. Background

21. Switching Between Certolizumab Pegol and Adalimumab After Anti-TNF Failure

22. Findings

23. Conclusions

24. Switching Biologic Therapy in RA Patients

25. Findings

26. Findings (cont)

27. Longer-Term Follow-Up on Therapies for Rheumatoid Arthritis

28. 3-Year Outcomes of Sarilumab in Patients With RA

29. Methods

30. Findings

31. Findings (cont)

32. Summary

33. Long-Term Outcomes With Tofacitinib Based on RAPID3 Responses at 6 Months

34. Outcome Measures

35. Findings

36. Findings (cont)

37. Conclusions

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)